Koselugo
Active Ingredient(s): Selumetinib SulfateFDA Approved: * April 10, 2020
Pharm Company: * ASTRAZENECA PHARMS
Category: Genetic Disorders
Selumetinib (INN),[6] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves.[7] It is taken by mouth.[3] Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle pain, as well as dry skin and other skin problems.... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.